- Home
- WAVE vs BCAB Comparison
WAVE vs BCAB Comparison
Compare WAVE & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAVE
- BCAB
- Stock Information
- Founded
- WAVE 2011
- BCAB 2007
- Country
- WAVE Israel
- BCAB United States
- Employees
- WAVE N/A
- BCAB N/A
- Industry
- WAVE Electric Utilities: Central
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- WAVE Utilities
- BCAB Health Care
- Exchange
- WAVE Nasdaq
- BCAB Nasdaq
- Market Cap
- WAVE 40.3M
- BCAB 40.5M
- IPO Year
- WAVE 2021
- BCAB 2020
- Fundamental
- Price
- WAVE $7.42
- BCAB $0.68
- Analyst Decision
- WAVE Strong Buy
- BCAB Hold
- Analyst Count
- WAVE 1
- BCAB 3
- Target Price
- WAVE $15.00
- BCAB $1.00
- AVG Volume (30 Days)
- WAVE 36.3K
- BCAB 1.1M
- Earning Date
- WAVE 11-11-2025
- BCAB 11-13-2025
- Dividend Yield
- WAVE N/A
- BCAB N/A
- EPS Growth
- WAVE N/A
- BCAB N/A
- EPS
- WAVE N/A
- BCAB N/A
- Revenue
- WAVE $168,000.00
- BCAB $11,000,000.00
- Revenue This Year
- WAVE $203.57
- BCAB N/A
- Revenue Next Year
- WAVE $160.00
- BCAB N/A
- P/E Ratio
- WAVE N/A
- BCAB N/A
- Revenue Growth
- WAVE N/A
- BCAB N/A
- 52 Week Low
- WAVE $4.41
- BCAB $0.24
- 52 Week High
- WAVE $17.63
- BCAB $2.53
- Technical
- Relative Strength Index (RSI)
- WAVE 44.14
- BCAB 48.77
- Support Level
- WAVE $6.76
- BCAB $0.60
- Resistance Level
- WAVE $7.97
- BCAB $0.69
- Average True Range (ATR)
- WAVE 0.48
- BCAB 0.07
- MACD
- WAVE -0.06
- BCAB -0.01
- Stochastic Oscillator
- WAVE 42.74
- BCAB 42.45
About WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.